Seventh International Congress on Drug Therapy in HIV Infection Glasgow, UK - 14-17 November 2004

Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL7.4

H.C. Bucher , T.R. Glass , C. Ungsedhapand , Swiss HIV Cohort Study
Basel Institute of Clinical Epidemiology, University Hospital Basel, Basel, Switzerland

To examine the extent of control and treatment of CHD risk factors in both treated and untreated individuals in the Swiss HIV Cohort Study (SHCS).

Since April 1, 2000, HIV-infected individuals enrolled in the SHCS are biannually assessed for CHD risk factors and cardiovascular events. All scheduled visits with lab values within 30 days are included in the analysis. Risk of CHD is predicted using Framingham risk scoring. Control of CHD risk factors was assessed according to the 3^rd National Cholesterol Education Program Adult Treatment Panel III, the 7^th Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and the American Diabetes Association. Treatment success was defined as achieving the recommended target levels on at least 80% of visits after initiating therapy.

A total of 6571 patients completed at least one CHD questionnaire between April 1, 2000 and March 31, 2003. Of these, 69% were males and 43% aged ≥ 40 years. From the first completed questionnaire, 51% of individuals were on HAART and 15.5% had a 10-20% and 3.3% had a >20% 10-year risk of CHD. According to guidelines, drug treatment was recommended at any visit in 458/2453 (18.7%) individuals with evaluable LDL cholesterol, 2150/6076 (35.4%) individuals for high systolic/diastolic blood pressure and 283/6406 (4.4%) individuals for diabetes. Of those receiving CHD drug treatment 82/165 (49.7%), 10/416 (2.4%) and 45/111 (40.5%) achieved recommended target values for LDL cholesterol, blood pressure and blood glucose respectively.

Large proportions of HIV-infected patients fulfill requirements for treatment of CHD risk factors and of those receiving drug treatment only a minority achieved recommended target levels.

SESSION 7: ADVERSE EVENTS I

2004-11-14
PL7.4

Copyright © 2004 - Thomson ACUMED® All rights reserved. Thomson ACUMED® is an intelligent and innovative medical marketing and communications agency – a new division of The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, located in Tytherington, UK.

Reproduction of this abstract (other than one copy for personal reference) must be cleared through the authors.

This information is designed to support, not replace, the relationship that exists between you and your doctor. ©1980, 2005. AEGiS.